Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients (Q42556657)

2 November 2017

title

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients (English)

1 reference

2 November 2017

1 reference

coronary artery disease

1 reference

2

A Hamsten

1 reference

2 November 2017

6

U de Faire

1 reference

2 November 2017

C G Ericsson

1

1 reference

2 November 2017

J Nilsson

series ordinal

3

1 reference

2 November 2017

L Grip

series ordinal

4

1 reference

2 November 2017

B Svane

series ordinal

5

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 March 1996

1 reference

2 November 2017

1 reference

2 November 2017

volume

347

1 reference

2 November 2017

issue

9005

1 reference

2 November 2017

page(s)

849-853

1 reference

Incidence and prognosis of acute myocardial infarction among men below age 40 in Göteborg, Sweden

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Glucose tolerance and insulin response to glucose in nondiabetic young male survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Risk factors for coronary artery disease in families of young men with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Haemostatic function in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Triglyceride-rich lipoproteins and the progression of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2991343-4

7 January 2021

10.1016/S0140-6736(96)91343-4

Identifiers

DOI

1 reference

2 November 2017

1 reference